SG11201407266PA - Polymorph compositions, methods of making, and uses thereof - Google Patents
Polymorph compositions, methods of making, and uses thereofInfo
- Publication number
- SG11201407266PA SG11201407266PA SG11201407266PA SG11201407266PA SG11201407266PA SG 11201407266P A SG11201407266P A SG 11201407266PA SG 11201407266P A SG11201407266P A SG 11201407266PA SG 11201407266P A SG11201407266P A SG 11201407266PA SG 11201407266P A SG11201407266P A SG 11201407266PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- agent
- park
- pct
- unless
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644523P | 2012-05-09 | 2012-05-09 | |
US13/800,480 US9399019B2 (en) | 2012-05-09 | 2013-03-13 | Polymorph compositions, methods of making, and uses thereof |
PCT/US2013/040265 WO2013169979A2 (en) | 2012-05-09 | 2013-05-09 | Polymorph compositions, methods of making, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407266PA true SG11201407266PA (en) | 2014-12-30 |
Family
ID=49548793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407266PA SG11201407266PA (en) | 2012-05-09 | 2013-05-09 | Polymorph compositions, methods of making, and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US9399019B2 (ko) |
EP (1) | EP2846775A4 (ko) |
JP (1) | JP6338573B2 (ko) |
KR (1) | KR101784260B1 (ko) |
CN (1) | CN104955445A (ko) |
AU (1) | AU2013259476B2 (ko) |
BR (1) | BR112014027965A2 (ko) |
CA (2) | CA2872887C (ko) |
GB (1) | GB2517096A (ko) |
HK (2) | HK1202264A1 (ko) |
IL (1) | IL235262A0 (ko) |
NZ (1) | NZ629727A (ko) |
RU (1) | RU2014149362A (ko) |
SG (1) | SG11201407266PA (ko) |
WO (1) | WO2013169979A2 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10092524B2 (en) * | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
US9399019B2 (en) * | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
CA2986692A1 (en) * | 2015-05-29 | 2016-12-08 | Edge Therapeutics, Inc. | Compositions and methods for reducing visual loss |
US20190054022A1 (en) * | 2016-04-07 | 2019-02-21 | Edge Therapeutics, Inc. | Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage |
CN105944152B (zh) * | 2016-06-13 | 2019-02-12 | 龙岩紫荆创新研究院 | 可吸收防粘医用膜的制备方法 |
WO2018039039A1 (en) * | 2016-08-23 | 2018-03-01 | Edge Therapeutics, Inc. | Scalable microparticulate formulations containing polymorphic nimodipine form 2 prepared by a solvent evaporation process |
WO2019018306A1 (en) * | 2017-07-17 | 2019-01-24 | Edge Therapeutics, Inc. | ADVANCED MICROPARTICULAR FORMULATIONS CONTAINING FORM 2 OF MICRONIZED POLYMORPHIC NIMODIPINE |
EP3848021A4 (en) * | 2018-09-08 | 2023-11-29 | Jiangsu Jiuxu Pharmaceutical Co., Ltd. | NIMODIPINE INJECTION COMPOSITION AND PROCESS FOR PRODUCTION THEREOF |
EP3861071A4 (en) * | 2018-10-04 | 2022-07-20 | Fardanov, Aleksandra | FLAVORED PLASTISOL BASED ON LIPOPHILIC POLYMER-FREE POLYVINYL CHLORIDE |
KR102181231B1 (ko) * | 2018-11-22 | 2020-11-20 | 주식회사 메디포럼제약 | 로티고틴 함유 고분자 미립자의 제조방법 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932645A (en) | 1971-04-10 | 1976-01-13 | Farbenfabriken Bayer Ag | Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid |
DE2117571C3 (de) | 1971-04-10 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel |
US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
ATE133087T1 (de) * | 1989-05-04 | 1996-02-15 | Southern Res Inst | Einkapselungsverfahren |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
IT1255792B (it) | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
CA2180526A1 (en) | 1994-01-05 | 1995-07-13 | Joseph C. Hogan, Jr. | Method of identifying chemical compounds having selected properties for a particular application |
US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
CA2250295C (en) | 1996-03-12 | 2008-12-30 | Pg-Txl Company L.P. | Water soluble paclitaxel prodrugs |
KR100236771B1 (ko) | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
US6123956A (en) | 1997-07-10 | 2000-09-26 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
US6224794B1 (en) | 1998-05-06 | 2001-05-01 | Angiotech Pharmaceuticals, Inc. | Methods for microsphere production |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
US6869551B2 (en) * | 2001-03-30 | 2005-03-22 | Picoliter Inc. | Precipitation of solid particles from droplets formed using focused acoustic energy |
US20040235801A1 (en) | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
BRPI0409032A (pt) | 2003-04-10 | 2006-05-02 | Pr Pharmaceuticals | método para a produção de micropartìculas à base de emulsão |
US20070207211A1 (en) | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
AU2004245057B2 (en) * | 2003-06-04 | 2008-07-31 | Alkermes Pharma Ireland Limited | Polymorphic forms of naltrexone |
CA2533592C (en) | 2003-07-23 | 2015-11-10 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
WO2006084005A2 (en) | 2005-02-02 | 2006-08-10 | University Of Vermont And State Agricultural College | Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage |
US20060217340A1 (en) | 2005-03-23 | 2006-09-28 | University Of Vermont And State Agricultural College | Methods and products for treating hypertension by modulation of TRPC3 channel activity |
CN101045054A (zh) | 2006-03-29 | 2007-10-03 | 上海医药工业研究院 | 尼莫地平纳米混悬剂冻干组合物、其制备方法及应用 |
JP2010526054A (ja) | 2007-05-01 | 2010-07-29 | シグモイド・ファーマ・リミテッド | 併用医薬組成物 |
WO2008154585A1 (en) * | 2007-06-11 | 2008-12-18 | Macdonald R Loch | A drug delivery system for the prevention of cerebral vasospasm |
US9364432B2 (en) | 2007-06-11 | 2016-06-14 | Edge Therapeutics, Inc. | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
ES2718612T3 (es) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
US20100008968A1 (en) | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
JP5757872B2 (ja) * | 2008-09-11 | 2015-08-05 | エボニック コーポレイションEvonik Corporation | 調整可能な抽出速度を有する溶媒抽出マイクロカプセル化 |
EP2334288B1 (en) | 2008-09-18 | 2021-05-19 | Evonik Corporation | Microencapsulation process with solvent and salt |
CN101416963A (zh) | 2008-12-02 | 2009-04-29 | 沈阳万爱普利德医药科技有限公司 | 注射用尼莫地平冻干亚微乳剂及其制备方法 |
US20100216948A1 (en) | 2009-01-23 | 2010-08-26 | Tipton Arthur J | Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same |
US20130059008A1 (en) | 2009-01-23 | 2013-03-07 | Jeffrey L. Atkinson | Drying methods for tuning microparticle properties |
JP2012515791A (ja) | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | ポリマー混成物由来の放出制御システム |
CN101485632B (zh) | 2009-02-11 | 2011-05-18 | 西安德天药业股份有限公司 | 尼莫地平脂质微球注射液及其制备方法 |
US20100291027A1 (en) | 2009-05-14 | 2010-11-18 | Jason Campbell | Hyaluronic acid (ha) injection vehicle |
ES2764971T3 (es) | 2009-12-22 | 2020-06-05 | Evonik Corp | Proceso basado en emulsión para la preparación de micropartículas y conjunto de cabezal de trabajo para su uso con el mismo |
CN102834104A (zh) | 2010-02-22 | 2012-12-19 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
US9504643B2 (en) | 2010-03-29 | 2016-11-29 | Evonik Corporation | Compositions and methods for improved retention of a pharmaceutical composition at a local administration site |
CN105997890A (zh) | 2011-02-11 | 2016-10-12 | 优势医疗公司 | 用于改善患有蛛网膜下腔出血的人的预后的组合物和方法 |
CN102274176B (zh) | 2011-08-04 | 2013-11-20 | 上海天氏利医药科技有限公司 | 一种尼莫地平注射液的组合物及其制备方法与应用 |
US9399019B2 (en) * | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
-
2013
- 2013-03-13 US US13/800,480 patent/US9399019B2/en not_active Expired - Fee Related
- 2013-05-09 BR BR112014027965A patent/BR112014027965A2/pt not_active Application Discontinuation
- 2013-05-09 NZ NZ629727A patent/NZ629727A/en not_active IP Right Cessation
- 2013-05-09 WO PCT/US2013/040265 patent/WO2013169979A2/en active Application Filing
- 2013-05-09 JP JP2015511680A patent/JP6338573B2/ja not_active Expired - Fee Related
- 2013-05-09 EP EP13787017.6A patent/EP2846775A4/en not_active Withdrawn
- 2013-05-09 AU AU2013259476A patent/AU2013259476B2/en not_active Ceased
- 2013-05-09 KR KR1020147034606A patent/KR101784260B1/ko active IP Right Grant
- 2013-05-09 CA CA2872887A patent/CA2872887C/en not_active Expired - Fee Related
- 2013-05-09 RU RU2014149362A patent/RU2014149362A/ru not_active Application Discontinuation
- 2013-05-09 CN CN201380023989.1A patent/CN104955445A/zh active Pending
- 2013-05-09 GB GB1418703.3A patent/GB2517096A/en active Pending
- 2013-05-09 SG SG11201407266PA patent/SG11201407266PA/en unknown
- 2013-05-09 CA CA2961123A patent/CA2961123A1/en not_active Abandoned
- 2013-07-16 US US13/943,547 patent/US8821944B1/en not_active Expired - Fee Related
-
2014
- 2014-10-22 IL IL235262A patent/IL235262A0/en unknown
-
2015
- 2015-03-19 HK HK15102813.4A patent/HK1202264A1/xx unknown
- 2015-08-31 HK HK15108503.6A patent/HK1207824A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1202264A1 (en) | 2015-09-25 |
EP2846775A2 (en) | 2015-03-18 |
BR112014027965A2 (pt) | 2017-06-27 |
CA2961123A1 (en) | 2013-11-14 |
RU2014149362A (ru) | 2016-06-27 |
US20130302431A1 (en) | 2013-11-14 |
US20140271895A1 (en) | 2014-09-18 |
KR20150021517A (ko) | 2015-03-02 |
GB2517096A (en) | 2015-02-11 |
NZ629727A (en) | 2016-06-24 |
JP6338573B2 (ja) | 2018-06-06 |
IL235262A0 (en) | 2014-12-31 |
KR101784260B1 (ko) | 2017-11-06 |
WO2013169979A3 (en) | 2015-06-18 |
CA2872887C (en) | 2017-08-22 |
JP2015522534A (ja) | 2015-08-06 |
GB201418703D0 (en) | 2014-12-03 |
US9399019B2 (en) | 2016-07-26 |
AU2013259476A1 (en) | 2014-10-30 |
EP2846775A4 (en) | 2016-04-13 |
CA2872887A1 (en) | 2013-11-14 |
WO2013169979A9 (en) | 2015-01-08 |
WO2013169979A2 (en) | 2013-11-14 |
CN104955445A (zh) | 2015-09-30 |
US8821944B1 (en) | 2014-09-02 |
HK1207824A1 (en) | 2016-02-12 |
AU2013259476B2 (en) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407266PA (en) | Polymorph compositions, methods of making, and uses thereof | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201408261UA (en) | Syringe | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
SG11201407971QA (en) | Paliperidone implant formulation | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201909243TA (en) | New bicyclic pyrazole derivatives | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors |